Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma (LA HPSCC)

被引：0
|
作者：
Zhang, Y. [1 ]
Gao, W. [1 ]
Feng, L. [1 ]
Zhao, X. [1 ]
Huang, Z. [1 ]
Chen, D. [1 ]
Yin, G. [1 ]
Guo, W. [1 ]
机构：
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.462
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma
    Gao, Wen
    Feng, Lifei
    Zhao, Xinming
    Huang, Zishi
    Chen, Duoxuan
    Yin, Gaofei
    Guo, Wei
    Zhong, Qi
    Chen, Xiaohong
    Fang, Jugao
    Zhang, Yang
    Huang, Zhigang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Qian, Ting
    Liu, Delin
    Cao, Guochun
    Chen, Zhipeng
    Zhang, Qin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [3] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
    Shen, Dijian
    Chen, Qixun
    Wu, Jie
    Li, Jianqiang
    Tao, Kaiyi
    Jiang, Youhua
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (01) : 1 - 10
  • [4] Nomogram Prediction of Response to Neoadjuvant Chemotherapy Plus Pembrolizumab in Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
    Hu, Zhangwei
    Chen, Yi
    Ma, Renqiang
    Sun, Wei
    Chen, Lin
    Cai, Zhimou
    Wen, Weiping
    Lei, Wenbin
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 54
  • [5] Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Lv, Huilai
    Tian, Yang
    Li, Jiachen
    Huang, Chao
    Sun, Bokang
    Gai, Chunyue
    Li, Zhenhua
    Tian, Ziqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer
    Xiong, Hui
    Li, Yun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (08): : 3559 - 3570
  • [7] Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
    Tian, Zhichao
    Yang, Yonghao
    Yang, Jinpo
    Zhang, Peng
    Zhang, Fan
    Du, Xinhui
    Li, Chao
    Wang, Jiaqiang
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 1339 - 1346
  • [8] Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study
    Liang, Haifeng
    Liang, Wenting
    Tian, Jiawang
    Zheng, Shibei
    Su, Yangzhou
    Huang, Piao
    Chen, Renhui
    Guan, Zhong
    Cai, Qian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
  • [9] Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
    He, J.
    Zhao, L.
    Li, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1553 - S1553
  • [10] A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma
    Shi, Y.
    An, X.
    Yan, R.
    Yao, K.
    Xue, C.
    Guo, S.
    Liu, T.
    Li, J.
    Ma, H.
    Tian, L.
    Zhou, F.
    Shi, Y.
    Han, H.
    EUROPEAN UROLOGY, 2021, 79 : S933 - S933
12345